Acétate d'octréotide CAS:83150-76-9

Usage : acétate d'octréotide, comme formulation à effet retard injectable pour le traitement des tumeurs productrices d'hormone de croissance (acromégalie et gigantisme).

La description :

Octréotide (nom de marque Sandostatine, Novartis Pharmaceutique) est un octapeptide qui imite pharmacologiquement la somatostatine naturelle, bien qu'il s'agisse d'un inhibiteur plus puissant de l'hormone de croissance, glucagon, et l'insuline que l'hormone naturelle. Il a été synthétisé pour la première fois dans 1979 by the chemist Wilfried Bauer.

Application :

Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinides overdose. It has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.

Octreotide has been used experimentally to treat obesity, particularly obesity caused by lesions in the hunger and satiety centers of the hypothalamus, a region of the brain central to the regulation of food intake and energy expenditure. The circuit begins with an area of the hypothalamus, the arcuate nucleus, that has outputs to the lateral hypothalamus (LH) and ventromedial hypothalamus (VMH), the brain’s feeding and satiety centers, respectivement. The VMH is sometimes injured by ongoing treatment for acute lymphoblastic leukemia (ALL) or surgery or radiation to treat posterior cranial fossa tumors.